Home › Acute Lymphoblastic Leukemia › Indiana
Acute Lymphoblastic Leukemia clinical trials in Indiana
6 studies for Acute Lymphoblastic Leukemia are looking for participants at sites in Indiana.
Cities in Indiana
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Reid Health, Richmond
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Riley Children's Hosptial, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT07586618The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Riley Hospital for Children, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Indiana University/Riley Hospital for Children, Indianapolis
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
- Ascentage Investigative Site #1158, Indianapolis
- Ascentage Investigative Site #1069, Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT06051409Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Riley Hospital for Children, Indianapolis
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.